TY - JOUR T1 - Budesonide–formoterol reliever therapy in intermittent <em>versus</em> mild persistent asthma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.03064-2020 VL - 57 IS - 2 SP - 2003064 AU - Alberto Papi AU - Irene Braithwaite AU - Stefan Ebmeier AU - Robert J. Hancox AU - Tim Harrison AU - Mark Holliday AU - Claire Houghton AU - Luca Morandi AU - Karen Oldfield AU - Ian D. Pavord AU - Helen K. Reddel AU - Mathew Williams AU - Mark Weatherall AU - Richard Beasley A2 - , Y1 - 2021/02/01 UR - http://erj.ersjournals.com/content/57/2/2003064.abstract N2 - Traditional asthma maintenance therapy in adults and adolescents comprises inhaled corticosteroids (ICS), with a long-acting β2-agonist (LABA) added if ICS monotherapy provides insufficient control [1, 2]. For patients with symptoms occurring on two or fewer occasions per week (so-called “intermittent” asthma [2]), who may represent around one-third of the asthma population [3], many guidelines still recommend short-acting β2-agonist (SABA) rescue medication alone [2, 4].These post hoc analyses of NovelSTART provide the first evidence that the exacerbation risk reduction with budesonide–formoterol reliever therapy versus salbutamol reliever therapy is similar in adults with intermittent and mild persistent asthma https://bit.ly/3iiRKqRWriting support was provided by David Young of Young Medical Communications and Consulting Ltd. This was funded by Consorzio Futuro in Ricerca, University of Ferrara, Ferrara, Italy. ER -